Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

116
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
116
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.9K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.9K
Pharmacovigilance01:19

Pharmacovigilance

2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

813
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
813
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.6K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.6K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

706
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
706

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes and cost-utility analysis of comprehensive geriatric assessment models in hospitalized frail older patients in Thailand.

BMC geriatrics·2026
Same author

Development and validation of an Online Comprehensive Geriatric Screening (O-CGS) Tool.

BMC public health·2026
Same author

Association of preoperative frailty and delayed neurocognitive recovery in older adults undergoing major elective surgery in Thailand: a single centre prospective study.

The Lancet regional health. Southeast Asia·2026
Same author

Cost-utility analysis of cerebrospinal fluid versus blood biomarkers for early detection of Alzheimer's disease and mild cognitive impairment in Thailand: a modeling study.

BMC health services research·2026
Same author

A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Multisectoral policy and health systems responses to ageing populations.

Bulletin of the World Health Organization·2026

Related Experiment Video

Updated: Apr 30, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.5K

Interaction between physicians and pharmaceutical representatives, an insight from Thailand.

Varalak Srinonprasert, Artit Arrunyagasamesuke, Akarin Nimmannit

    Journal of the Medical Association of Thailand = Chotmaihet Thangphaet
    |April 30, 2014
    PubMed
    Summary

    Resident physicians in Thailand frequently interact with pharmaceutical representatives, receiving gifts monthly. This interaction frequency may indicate exposure but not necessarily influence prescribing behavior, highlighting a need for conflict-of-interest training.

    More Related Videos

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    9.6K
    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.2K

    Related Experiment Videos

    Last Updated: Apr 30, 2026

    Ole Isacson: Development of New Therapies for Parkinson's Disease
    23:53

    Ole Isacson: Development of New Therapies for Parkinson's Disease

    Published on: April 29, 2007

    7.5K
    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
    05:10

    Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

    Published on: December 11, 2016

    9.6K
    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.2K

    Area of Science:

    • Medical Education
    • Pharmaceutical Marketing
    • Health Policy

    Background:

    • Western evidence links pharmaceutical industry-physician relationships to prescribing behavior.
    • Conflict-of-interest policies aim to mitigate these effects.
    • Physician-pharmaceutical representative interactions in Thailand lack systematic study.

    Purpose of the Study:

    • To quantify interactions between pharmaceutical representatives and resident physicians in Thailand.
    • To assess resident physicians' attitudes towards these interactions.
    • To identify factors influencing the frequency of these interactions.

    Main Methods:

    • Anonymous, self-administered questionnaire survey.
    • 970 resident physicians surveyed at a Thai university hospital in May 2009.
    • Analysis of returned questionnaires.

    Main Results:

    • 71.6% response rate.
    • Three-fourths of residents had weekly contact with pharmaceutical representatives.
    • Nearly 90% received at least one gift monthly; higher interaction in high-cost prescribing specialties.
    • Perception of politeness influenced gift acceptance (OR 1.68).

    Conclusions:

    • Frequent interaction may be a marker of exposure rather than direct influence on prescribing.
    • Resident physicians in Thailand have substantial interaction with pharmaceutical representatives.
    • Conflict-of-interest management guidance is recommended for medical training.